Tokyo Tape
Sign in
← Kaken Pharmaceutical

Quarterly report · Q2

4521.TEDINET S100S89K
Period2023-04-01 → 2023-09-30
Filed2023-11-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
MetricValuePeriodScopeSource row
Revenue¥36.2bn2023-04-01 → 2023-09-30Cons.Net sales
Revenue¥73.0bn2022-04-01 → 2023-03-31Cons.Net sales (5-year summary)
Revenue¥36.8bn2022-04-01 → 2022-09-30Cons.Net sales
Operating income¥5.5bn2023-04-01 → 2023-09-30Cons.Operating income
Operating income¥8.2bn2022-04-01 → 2022-09-30Cons.Operating income
Ordinary income¥5.7bn2023-04-01 → 2023-09-30Cons.Ordinary income
Ordinary income¥8.7bn2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥8.6bn2022-04-01 → 2022-09-30Cons.Ordinary income
Profit before tax¥5.7bn2023-04-01 → 2023-09-30Cons.Income before income taxes
Profit before tax¥8.2bn2022-04-01 → 2022-09-30Cons.Income before income taxes
Net income (owners)¥4.1bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥5.4bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥6.0bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income¥4.1bn2023-04-01 → 2023-09-30Cons.Profit loss
Net income¥6.0bn2022-04-01 → 2022-09-30Cons.Profit loss
Total assets¥171.7bnat 2023-09-30Cons.Assets
Total assets¥166.3bnat 2023-03-31Cons.Assets
Total assets¥167.3bnat 2022-09-30Cons.Total assets (5-year summary)
Total liabilities¥30.9bnat 2023-09-30Cons.Liabilities
Total liabilities¥29.5bnat 2023-03-31Cons.Liabilities
Net assets / equity¥140.7bnat 2023-09-30Cons.Net assets
Net assets / equity¥136.8bnat 2023-03-31Cons.Net assets
Net assets / equity¥140.4bnat 2022-09-30Cons.Net assets (5-year summary)
Cash and deposits¥55.4bnat 2023-09-30Cons.Cash and deposits
Cash and deposits¥59.6bnat 2023-03-31Cons.Cash and deposits
Cash & equivalents¥70.1bnat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥74.3bnat 2023-03-31Cons.Cash and cash equivalents
Cash & equivalents¥75.5bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥74.6bnat 2022-03-31dCons.Cash and cash equivalents
Operating cash flow−¥245m2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥9.3bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥6.4bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥1.1bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥2.6bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥1.4bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥2.8bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥7.0bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥4.2bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥108.182023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥41.292023-07-01 → 2023-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥144.82022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥158.342022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥81.452022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
Equity ratio82.0%at 2023-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio81.9%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio83.6%at 2022-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 18
SegmentItemPeriodValue
jpcrp040300-q2r_E00935-000Medicinereportable segmentrevenue2023-04-01 → 2023-09-30¥35.0bn
jpcrp040300-q2r_E00935-000Medicinereportable segmentrevenue external2023-04-01 → 2023-09-30¥35.0bn
jpcrp040300-q2r_E00935-000Medicinereportable segmentsegment profit2023-04-01 → 2023-09-30¥4.9bn
jpcrp040300-q2r_E00935-000Real Estatereportable segmentrevenue2023-04-01 → 2023-09-30¥1.2bn
jpcrp040300-q2r_E00935-000Real Estatereportable segmentrevenue external2023-04-01 → 2023-09-30¥1.2bn
jpcrp040300-q2r_E00935-000Real Estatereportable segmentsegment profit2023-04-01 → 2023-09-30¥661m
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-09-30¥36.2bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-09-30¥36.2bn
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-09-30¥5.5bn
jpcrp040300-q2r_E00935-000Medicinereportable segmentrevenue2022-04-01 → 2022-09-30¥35.6bn
jpcrp040300-q2r_E00935-000Medicinereportable segmentrevenue external2022-04-01 → 2022-09-30¥35.6bn
jpcrp040300-q2r_E00935-000Medicinereportable segmentsegment profit2022-04-01 → 2022-09-30¥7.6bn
jpcrp040300-q2r_E00935-000Real Estatereportable segmentrevenue2022-04-01 → 2022-09-30¥1.2bn
jpcrp040300-q2r_E00935-000Real Estatereportable segmentrevenue external2022-04-01 → 2022-09-30¥1.2bn
jpcrp040300-q2r_E00935-000Real Estatereportable segmentsegment profit2022-04-01 → 2022-09-30¥616m
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-09-30¥36.8bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-09-30¥36.8bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-09-30¥8.2bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 501
ItemContextValueUnit
Other nclPrior1YearInstant414000000JPY
Other nclCurrentQuarterInstant556000000JPY
Noncurrent liabilitiesPrior1YearInstant8653000000JPY
Noncurrent liabilitiesCurrentQuarterInstant8762000000JPY
LiabilitiesPrior1YearInstant29491000000JPY
LiabilitiesCurrentQuarterInstant30922000000JPY
Capital stockPrior1YearInstant23853000000JPY
Capital stockCurrentQuarterInstant23853000000JPY
Capital surplusPrior1YearInstant11406000000JPY
Capital surplusCurrentQuarterInstant11462000000JPY
Retained earningsPrior1YearInstant126135000000JPY
Retained earningsCurrentQuarterInstant127390000000JPY
Treasury stockPrior1YearInstant-30026000000JPY
Treasury stockCurrentQuarterInstant-28612000000JPY
Shareholders equityPrior1YearInstant131368000000JPY
Shareholders equityCurrentQuarterInstant134093000000JPY
Valuation difference on available for sale securitiesPrior1YearInstant4724000000JPY
Valuation difference on available for sale securitiesCurrentQuarterInstant6472000000JPY
Remeasurements of defined benefit plansPrior1YearInstant165000000JPY
Remeasurements of defined benefit plansCurrentQuarterInstant162000000JPY
Valuation and translation adjustmentsPrior1YearInstant4889000000JPY
Valuation and translation adjustmentsCurrentQuarterInstant6635000000JPY
Non controlling interestsPrior1YearInstant578000000JPY
Non controlling interestsCurrentQuarterInstant－JPY
Net assetsPrior1YearInstant136836000000JPY
Net assetsCurrentQuarterInstant140728000000JPY
Liabilities and net assetsPrior1YearInstant166328000000JPY
Liabilities and net assetsCurrentQuarterInstant171651000000JPY
Net salesPrior1YTDDuration36819000000JPY
Net salesCurrentYTDDuration36171000000JPY
Cost of salesPrior1YTDDuration16432000000JPY
Cost of salesCurrentYTDDuration16450000000JPY
Gross profitPrior1YTDDuration20387000000JPY
Gross profitCurrentYTDDuration19720000000JPY
Salaries sgaPrior1YTDDuration2815000000JPY
Salaries sgaCurrentYTDDuration2821000000JPY
Bonuses and provision for bonuses sgaPrior1YTDDuration606000000JPY
Bonuses and provision for bonuses sgaCurrentYTDDuration553000000JPY
Retirement benefit expenses sgaPrior1YTDDuration170000000JPY
Retirement benefit expenses sgaCurrentYTDDuration136000000JPY
Research and development expenses sgaPrior1YTDDuration4330000000JPY
Research and development expenses sgaCurrentYTDDuration5738000000JPY
Other sgaPrior1YTDDuration4255000000JPY
Other sgaCurrentYTDDuration4957000000JPY
Selling general and administrative expensesPrior1YTDDuration12178000000JPY
Selling general and administrative expensesCurrentYTDDuration14207000000JPY
Operating incomePrior1YTDDuration8209000000JPY
Operating incomeCurrentYTDDuration5512000000JPY
Interest income noiPrior1YTDDuration3000000JPY
Interest income noiCurrentYTDDuration4000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2023-03-31pass rounding
balance sheet identityconsolidated 2023-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-09-30pass